SPOTLIGHT: Targeted Genetics hits back against trial report

Targeted Genetics went on the attack after The Washington Post raised serious criticisms of a gene therapy trial that was suspended after the death of a volunteer. But Wired also notes that the company's response avoids many of the most serious criticisms leveled in the report. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.